U.S. top court rejects Amgen over cholesterol medication patent fight

January 7, 2019 by  
Filed under News

Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial.

Source: Reuters Business News

Comments are closed.